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posite International Diagnostic Interview for mental disor-
ders adapted for cancer patients (CIDI-O).  Results: The over-
all 12-month prevalence for any mental disorder was 39.4% 
(95% CI: 37.3–41.5), that for anxiety disorders was 15.8% 
(95% CI: 14.4–17.4), 12.5% (95% CI: 11.3–14.0) for mood dis-
orders, 9.5% (95% CI: 8.3–10.9) for somatoform disorders, 
7.3% (95% CI: 6.2–8.5) for nicotine dependence, 3.7% (95% 
CI: 3.0–4.6) for disorders due to general medical condition, 
and 1.1% (95% CI: 0.7–1.6) for alcohol abuse or dependence. 
Lifetime prevalence for any mental disorder was 56.3% (95% 
CI 54.1–58.6), that for anxiety disorders was 24.1% (95% CI: 
22.3–25.9), 20.5% (95% CI: 18.9–22.3) for mood disorders, 
19.9% (95% CI: 18.3–21.7) for somatoform disorders, 18.2% 
(95% CI: 16.6–20.0) for nicotine dependence, 6.4% (95% CI: 
5.4–7.6) for alcohol abuse or dependence, 4.6% (95% CI: 3.8–
5.6) for disorders due to general medical condition, and 0.2% 
(95% CI: 0.1–0.6) for eating disorders.  Conclusions: Mental 
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 Abstract 
 Background: Psychological problems are common in cancer 
patients. For the purpose of planning psycho-oncological in-
terventions and services tailored to the specific needs of dif-
ferent cancer patient populations, it is necessary to know to 
what extent psychological problems meet the criteria of 
mental disorders. The purpose of this study was to estimate 
the 12-month and lifetime prevalence rates of mental disor-
ders in cancer patients.  Methods: A representative sample of 
patients with different tumour entities and tumour stages
(n = 2,141) in outpatient, inpatient and rehabilitation set-
tings underwent the standardized computer-assisted Com-
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disorders are highly prevalent in cancer patients, indicating 
the need for provision of continuous psycho-oncological 
support from inpatient to outpatient care, leading to an ap-
propriate allocation of direct personnel and other resources. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Many studies have shown high levels of emotional and 
psychosocial distress in cancer patients  [1–5] . However, 
it is not well understood yet to what extent psychological 
problems meet the criteria of a mental disorder according 
to clinical diagnostic classification systems (ICD-10, 
DSM-IV/V)  [6–8] – particularly with regard to the 
12-month and lifetime prevalence. The presence of men-
tal disorders and elevated levels of psychosocial distress 
in cancer patients can cause serious problems including 
reduced adherence and participation in medical care, in-
creased mortality, length of hospital stay, more suffering 
of somatic side effects, and poorer quality of life  [9–12] .
 Valid data about the prevalence of detected clinical di-
agnoses and thereby discrimination of mental disorders, 
subsyndromal disorders and mood changes in terms of 
psychological adaptation to the diagnosis of cancer and 
its treatment consequences are however essential for the 
implementation of specialized psychosocial and psycho-
logical services within the oncology care system. 
 Diagnosing mental disorders in oncology care settings 
is often impeded by a lack of relevant skills to diagnose 
mental disorders among the medical team, lack of time, 
unawareness of mental disorders in clinical practice, re-
luctance of patients to speak about psychological prob-
lems and the high variability of the onset of mental disor-
ders  [13–15] . Furthermore, it remains unclear whether a 
particular symptom, such as difficulty concentrating or 
weight loss, is a consequence of a treatment such as che-
motherapy, or a symptom of a mental disorder such as 
depression.
 Previous studies that have investigated the prevalence 
of mental comorbidity using a clinical psychiatric inter-
view as the ‘gold standard’ have been limited by relatively 
small samples predominantly including breast cancer pa-
tients  [16] . Meta-analyses and reviews furthermore indi-
cate that only few studies have assessed the 12-month and 
lifetime prevalence of mental disorders in cancer so far 
 [17, 18] . Results of these meta-analyses show a mean 
12-month prevalence of 18% for mood disorders, 19% for 
anxiety disorders and 8% for somatoform disorders with 
a large variability between studies. Lifetime prevalence 
rates of 21% for anxiety disorders, 21% for adjustment 
disorders, 26% for mood disorders, and 16% for somatic 
disorders have been reported  [17, 18] .
 Recently, we reported the 4-week prevalence of any 
mental disorder (31.8%; 95% CI 29.8–33.8) as a result of 
a large representative epidemiological study assessing 
psychological comorbidity in cancer patients  [19, 20] . 
Given the fact that early diagnosis and advanced multi-
modal treatments lead to a higher number of cancer sur-
vivors and many patients receive long-term treatments, 
the 12-month prevalence rates are of particular impor-
tance for health care planning. Mental disorders could be 
a long-lasting problem for cancer survivors  [21] leading 
to an increased risk for further somatic and psychological 
symptom burden.
 Today, high-quality cancer care is needed for longer 
periods of time after diagnosis and primary treatments 
and should provide comprehensive concepts of psycho-
social care considering the continuum of distress includ-
ing mental disorders distinct from emotional distress 
 [22] . In addition to the 4-week and 12-month prevalence, 
data on the lifetime prevalence of mental disorders are 
useful to better evaluate mental comorbidity across vari-
ous cancer entities in the light of population-based demo-
graphic data  [23, 24] .
 Given the potentially adverse effects of a pre-existing 
or emerging diagnosis of a mental disorder on a variety 
of treatment outcomes and quality of life in cancer pa-
tients, we investigated the 12-month and lifetime preva-
lence of mental disorders in a representative sample of 
cancer patients treated in different care settings in order 
to provide epidemiological data for evidence-based psy-
cho-oncological care planning. We analysed the impact 
of cancer care settings as well as of basic demographic and 
medical variables on the 12-month prevalence estimates. 
Further aims were to provide diagnostically detailed in-
formation about the 12-month and lifetime prevalence of 
mental disorders for patient populations of the most 
common cancer sites
 Methods 
 Study Design and Patients 
 We conducted a multicentre, epidemiological cross-sectional 
study in which we consecutively recruited cancer patients across 
all major tumour entities and disease stages from acute care hos-
pitals, outpatient cancer care facilities, and cancer rehabilitation 
clinics in Germany. Individuals were eligible if they had a diagno-
sis of a malignant tumour; were aged between 18 and 75 years, and 
able to speak and read German. Approval was obtained from the 
ethics committees of all participating centres (university medical 
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centres of Hamburg-Eppendorf, Freiburg, Heidelberg, Leipzig, 
and Würzburg, Germany). All participants provided written, in-
formed consent. The study methodology is described in detail else-
where  [19, 25] .
 Eligible patients were screened with the depression module of 
the Patient Health Questionnaire (PHQ-9)  [26] . Patients with a 
score of  ≥ 9 were selected for a personal interview with the CIDI-O 
as was a random sample of those with a PHQ-9 score <9. Using the 
CIDI-O, we assessed both the 12-month and lifetime prevalence of 
the following disorders according to the DSM-IV and ICD-10: 
mental disorders resulting from a general medical condition, sub-
stance use disorders (dependence and abuse of alcohol and nico-
tine), mood disorders (unipolar and bipolar), anxiety disorders 
(including acute and posttraumatic stress disorder; without obses-
sive compulsive disorder), somatoform disorders and eating dis-
orders. Schizophrenia and psychotic disorders were not assessed. 
Cancer-related adjustment disorders were estimated only for the 
last 4-week period as described elsewhere  [19] . 
 Measures  
 We used the PHQ-9  [26] , a patient self-report measure for de-
pressive symptoms based on the DSM-IV diagnostic criteria for 
major depressive disorder, as a screening tool (cut-off point of  ≥ 9) 
 [27] . 
 To estimate the prevalence of mental disorders, we used the 
standardized computer-assisted CIDI-O  [28] that is based on the 
Munich-Composite International Diagnostic Interview in the 
DIA-X version and was further developed for our specific study 
purposes  [29] . Further details about the application of the CIDI-O 
are described elsewhere  [19] . 
 Statistical Analysis 
 We calculated prevalence estimates (number of patients, per-
centage, and SE) with weights to compensate for the oversampling 
of patients with a PHQ score  ≥ 9. Statistical inference (SEs, CIs, and 
p values) was based on the Huber-White sandwich estimator of 
variance  [30–32] . Furthermore, a weighted logistic regression 
model with tumour entity, gender, cancer remission, cancer care 
settings, age groups and time since cancer diagnosis as predictors 
for the presence of any mental disorder in the last 12-month was 
used. Odds ratios and marginal means with corresponding 95% 
CIs were reported. Nominal p values are reported without correc-
tion for multiplicity. Two-sided p < 0.05 were considered signifi-
cant. All analyses were computed using STATA 12.1 (STATA, Col-
lege Station, Tex., USA).
 Results 
 Participants 
 A total of 5,889 cancer patients fulfilled the inclusion 
criteria. 4,020 (68.3%) patients had agreed to participate 
in the study. Among those, 2,710 patients were selected 
to be interviewed with the CIDI-O. 569 patients could not 
be reached (e.g. due to early discharge) or refused par-
ticipation. In total, 2,141 patients (79.0%) completed the 
CIDI-O. Of these, 1,103 (51.5%) were female and 1,358 
patients (63.4) were married ( table 1 ). The mean age was 
57.6 years (range 18–75). We conducted the interviews 
mostly during inpatient care (43.5%), followed by outpa-
tient care (29.9%) and inpatient rehabilitation (26.6%). 
The average time since current cancer diagnosis was 13.5 
months (range 0–126).
 Non-responder analyses showed that study partici-
pants were significantly younger, had a higher school ed-
ucation, and were more likely treated in a rehabilitation 
clinic than during inpatient acute care. Differences in 
non-responder rates were found between study centres. 
Furthermore, patients with male genital cancers as well as 
patients with cancers of the respiratory and intrathoracic 
organs were significantly more likely to refuse study par-
ticipation  [19] .
 Table 1.  Sociodemographic and medical sample characteristics
(n = 2,141)
Demographic characteristics
Mean age ± SD, years 57.6 ± 11.1
Female 1,103 (51.5)
Married 1,358 (63.4)
Education
High school/university degree 666 (31.1)
Other 1,475 (68.9)
Occupational situation
Employed 823 (38.4)
Retired 861 (40.2)
Other 457 (21.4)
Medical characteristics
Setting 
Inpatient 932 (43.5)
Outpatient 640 (29.9)
(Inpatient) rehabilitation 569 (26.6)
Tumor entity
Breast 442 (20.6)
Prostate 318 (14.9)
Colon/rectum 293 (13.7)
Lung 189 (8.8)
Female genital organs 183 (8.5)
Haematological cancers 170 (7.9)
Stomach/oesophagus 85 (4.0)
Kidney/urinary tract 74 (3.5)
Head and neck 67 (3.1)
Bladder 54 (2.5)
Pancreas 52 (2.4)
Malignant melanoma 34 (1.6)
Other 180 (8.5)
Mean time since current diagnosis ± SD, months 13.5 ± 24.9
Figures are numbers with percentages in parentheses unless 
indicated otherwise.
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 Table 2.  Twelve-month and lifetime prevalence of mental disorders (CIDI-O) for the total sample (n = 2,141)a
ICD Code Mental disorder 12-month Lifetime
prevalence
%
95% CI prevalence 
%
 95% CI
lower upper low er upper
Any mental disorder 39.4 37.3 41.5 56.3 54.1 58.6
Any anxiety disorder 15.8 14.4 17.4 24.1 22.3 25.9
(Panic attack) 7.6 6.6 8.8 12.5 11.2 14.0
(Panic attack with or w/o agoraphobia) 3.1 2.5 3.9 5.3 4.4 6.3
F41.0 Panic disorder w/o agoraphobia 1.6 1.2 2.2 3.1 2.5 4.0
F40.01 Panic disorder with agoraphobia 1.5 1.1 2.1 2.2 1.7 2.8
F40.00 Agoraphobia w/o history of panic disorder 2.7 2.1 3.5 4.0 3.3 4.9
Agoraphobia w/o panic disorder 3.3 2.6 4.1 5.0 4.2 6.0
F41.1 Generalized anxiety disorder 2.1 1.6 2.7 2.1 1.6 2.7
F43.1 Posttraumatic stress disorder 2.6 2.0 3.3 4.9 4.1 5.9
F40.2 Any specific (simple) phobia 6.8 5.8 7.9 9.6 8.4 10.9
Animal type 1.2 0.8 1.8 1.5 1.0 2.1
Natural environment type 2.8 2.2 3.6 4.9 4.1 5.9
Blood-injection-injury type 2.4 1.8 3.1 3.0 2.4 3.8
Situational type 2.1 1.6 2.8 3.4 2.7 4.3
Other type 0.4 0.3 0.8 0.6 0.3 1.0
F40.1 Social phobia 2.2 1.6 2.9 2.3 1.7 3.0
F41.9 Anxiety disorder NOS 2.3 1.8 3.1 5.4 4.5 6.5
Any mood disorder 12.5 11.3 14.0 20.5 18.9 22.3
F32.x/F33.x Any major depression (single or recurrent episode) 10.3 9.1 11.6 18.2 16.6 19.9
F32.x Any major depression, single episode 5.5 4.6 6.5 11.2 10.0 12.7
F33.x Any major depression, recurrent episodes 4.8 4.0 5.8 6.9 5.9 8.1
F34.1 Dysthymic disorder 4.4 3.7 5.2 4.7 4.0 5.6
Any single hypomanic or manic episode 0 – 0 –
Any somatoform/conversion disorder/syndrome 9.5 8.3 10.9 19.9 18.3 21.7
F45.4 Pain disorder 4.7 3.9 5.7 10.4 9.2 11.8
F45.1 Undifferentiated somatization disorder 0.2 0.1 0.5 0.3 0.1 0.7
F45.0 Somatization disorder 0 – 0 –
F44.xx Conversion disorder 0 – 0 –
45.2 Hypochondriasis 0 – 0 –
Som./diss. syndrome 4.7 3.8 5.7 9.4 8.2 10.8
Any somatoform/ conversion disorder 4.7 3.9 5.7 10.4 9.2 11.8
Any somatoform/conv. syndrome 4.8 4.0 5.9 9.7 8.5 11.1
Any disorder due to GMC 3.7 3.0 4.6 4.6 3.8 5.6
F06.3x Mental disorder due to GMC: depression 2.2 1.7 2.8 2.7 2.1 3.4
Mood disorder due to GMC: mania or mixed mood 0 – 0 –
F06.4x Anxiety disorder due to GMC: 1.2 0.8 1.8 1.5 1.0 2.1
Anxiety disorder with panic attacks due to GMC 0.4 0.2 0.7 0.5 0.3 0.8
Generalized anxiety disorder due to GMC 0.6 0.4 1.0 0.7 0.4 1.1
Any alcohol abuse or alcohol/nicotine dependence 8.1 7.0 9.4 21.8 20.1 23.7
F10.1/2x Alcohol abuse or dependence 1.1 0.7 1.6 6.4 5.4 7.6
F17.2x Nicotine dependence 7.3 6.2 8.5 18.2 16.6 20.0
Any eating disorder 0 – 0.2 0.1 0.6
F50.0 Anorexia nervosa 0 – 0 –
Atypical anorexia nervosa 0 – 0 –
F50.2 Bulimia nervosa 0 – 0.1 0.0 0.4
Atypical bulimia nervosa 0 – 0.2 0.1 0.4
F43.x Cancer-related adjustment disorderb 11.1 9.7 12.4 11.1 9.7 12.4
NOS = Not otherwise specified; GMC = general medical condition; ICD = International Classification of Diseases.
a On the basis of the 2,141 CIDI-O interviews, prevalence estimates were calculated for the total sample of 4,020 patients with weights for compensation 
of the oversampling of patients with a PHQ score ≥9. b The prevalence of cancer-related adjustment disorder refers to a 4-week period only. 
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 Overall 12-Month Prevalence Estimates 
 The 12-month prevalence of mental disorders in cancer 
patients was 39.4% (35.7% without alcohol abuse/depen-
dency and nicotine dependency). Most prevalent axis I 
mental disorders were anxiety disorders (15.8%) and mood 
disorders (12.5%). Within the spectrum of anxiety disor-
ders, specific phobias were most prevalent (6.8%).  Table 2 
shows the prevalence rates for axis I mental disorders. 
 Overall Lifetime Prevalence Estimates  
 The overall lifetime prevalence was 56.3% for any axis 
I mental disorder (47.6% without alcohol abuse/depen-
dency and nicotine dependency). Major groups of mental 
disorders were anxiety disorder (24.1%), mood disorders 
(20.5%) and nicotine dependence and/or alcohol depen-
dence/abuse (21.8%) ( table 2 ). 
 12-Month Prevalence Estimates by Tumour Entity 
 The 12-month prevalence of any axis I mental disorder 
between distinct tumour entities ranged between 30.4 
and 59.2% (online suppl. table; for all online suppl. mate-
rial, see www.karger.com/doi/10.1159/000446991). Pa-
tients with head and neck cancer (59.2%), breast cancer 
(47.8%), kidney/urinary tract cancer (45.5%) or female 
genital cancer (45.0%) were most frequently diagnosed 
with an axis I mental disorder. The lowest prevalence of 
any axis I mental disorder was found in patients with 
prostate cancer (26.5%) and pancreas cancer (30.4%) fol-
lowed by patients with stomach/oesophagus cancer 
(34.1%) (online suppl. table). 
 Lifetime Prevalence Estimates by Tumour Entity 
 The highest lifetime prevalence of any axis I mental 
disorder was found in head and neck cancer patients 
(69.9%), patients with malignant melanoma (66.1%) and 
patients with breast cancers (63%). The lowest prevalence 
of any axis I mental disorder had patients with prostate 
cancer (47%), pancreas cancer (48.1%), or bladder cancer 
(50.6%) (online suppl. table).
 12-Month Prevalence Estimates Depending on 
Demographic and Medical Factors 
 Table 3 shows the regression analysis on the impact of 
demographic and medical factors on the 12-month prev-
alence estimates of any mental disorder. Head and neck 
cancer patients had a significantly higher risk for having 
any mental disorder (predicted marginal probability 
58.7%; 95% CI: 46.4–71.1) in comparison to most of the 
other tumour entities, except for bladder (49.9%; 95% CI: 
34.6–65.2), kidney/urinary tract cancer patients (46.9%; 
95% CI: 34.1–59.8) and patients with malignant melano-
ma (37.8%; 95% CI: 19.8–55.7). Yet, we did not find an 
overall significant effect of tumour entity on the 12-month 
prevalence estimates of any mental disorder (p = 0.179). 
We found men having a significantly lower risk for hav-
ing any mental disorder than women with 29.6% (95% CI: 
26.0–33.3) and 47.9% (95% CI: 43.7–52.0), respectively. 
Patients between 40 and 49 years (41.9%; 95% CI: 36.1–
47.7) and patients older than 60 years (60–69 years: 34.8%; 
95% CI: 31.0–38.7 and 70–75 years: 29.4%; 95% CI: 23.6–
35.3) were found to have a significantly decreased risk for 
having any mental disorder compared to patients young-
er than 40 years (53.6%; 95% CI: 43.8–63.4). Patients who 
were diagnosed with cancer more than 12 months but less 
than 24 months ago also had a significantly higher risk of 
having any mental disorder compared to patients who 
were diagnosed in the last 6 months (48.0%; 95% CI: 
40.8–55.3 vs. 36.0%; 95% CI: 32.9–39.1). We found no 
significant difference between patients with cancer re-
mission and those with no cancer remission as well as 
between inpatient and outpatient cancer care settings.
 Discussion 
 In this multicentre epidemiological study, we aimed to 
provide comprehensive and reliable estimates of the 
12-month and lifetime prevalence of axis I mental disor-
ders in cancer patients across major tumour entities using 
a standardized clinical interview. Our findings showed a 
total prevalence of any mental disorder in 39.4% of pa-
tients over a 12-month period and a 56.3% lifetime prev-
alence. The most frequent mental disorders were anxiety 
disorder (15.8 and 24.1%, respectively) and mood disor-
ders (12.5 and 20.5%, respectively). 
 Meta-analyses of German studies using standardized 
clinical interviews in cancer populations showed lower 
12-month prevalence rates for mood disorders (12.6 vs. 
18%), anxiety disorders (15.8 vs. 19%) and slightly higher 
rates for somatoform disorders (9.5 vs. 8%)  [17, 18] . We 
also found lower lifetime prevalence rates for mood dis-
orders (20.5 vs. 26%) and anxiety disorders (24.1 vs. 30%) 
compared to the meta-analyses of studies with German 
patients. Compared to international studies, we found a 
higher lifetime prevalence of any anxiety disorder (24.1 
vs. 21%)  [17] . However, comparisons of findings with 
previous studies are limited by the fact that other studies 
used different time frames of assessment and different di-
agnostic conventions and thus should be interpreted with 
caution. 
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 As expected, the findings of our previous work  [19] 
revealed that the 4-week prevalence (31.8%) is lower than 
12-month (39.4%) and lifetime prevalence (56.3%), al-
though we need to consider that the 11% adjustment dis-
order refers to the 4-week prevalence but is included into 
the 12-month and lifetime prevalence estimates. 
 The 12-month and lifetime prevalence estimates 
showed a higher percentage increase of any mood disor-
der compared to the 4-week prevalence rates than any 
other mental disorder. Our higher rates for 12-month 
mood disorders seem to be a more appropriate indication 
of the true morbidity rate than the 4-week diagnoses, be-
cause they describe the psychopathology and course of 
affective syndromes more appropriately and take into ac-
count that many subjects with threshold diagnoses in the 
past 12 months are likely to be only partially remitted. 
Further the 12-month time frame takes better into ac-
count the middle- and long-term consequences of the 
cancer and cancer treatments such as fatigue, pain, lower 
quality of life, illness perceptions and maladaptive coping 
strategies  [33, 34] .
 Prevalence estimates differ widely between different 
tumour entities, which is in accordance with previous 
findings based on patients’ self-report  [16, 35, 36] . Mental 
disorders were more frequently diagnosed in patients with 
breast cancer, head and neck cancer, malignant melano-
ma and kidney/urinary tract cancers. Lower prevalence 
rates were observed in patients with pancreas cancer, 
stomach/oesophagus cancer, prostate cancer and bladder 
cancer. However, we did not find any significant differ-
 Table 3.  Regression analysis on 12-month prevalence estimates of any mental disorders (CIDI-O)
Characteristics OR  95% CI p p(global)
l ower upper
Tumor entity Breast 0.92 0.62 1.36 0.666 0.179
Prostate 1.00 0.66 1.51 0.987
Colon/rectuma
Female genital organs 0.74 0.47 1.18 0.206
Lung 0.91 0.56 1.48 0.704
Bladder 1.61 0.78 3.30 0.194
Hematological malignancies 0.95 0.60 1.49 0.815
Stomach/oesophagus 0.93 0.52 1.68 0.816
Kidney/urinary tract 1.41 0.76 2.64 0.278
Malignant melanoma 0.94 0.39 2.24 0.889
Head and neck 2.37 1.28 4.39 0.006
Pancreas 0.73 0.34 1.53 0.399
Other 1.00 0.63 1.59 0.997
Remission (tumor-free) No 1.16 0.91 1.48 0.235
Yesa
Sex Femalea
Male 0.45 0.34 0.59 <0.001
Setting Inpatient care/hospital carea .608
Outpatient care 1.14 0.88 1.47 0.323
(Inpatient) rehabilitation clinic 1.09 0.81 1.47 0.575
Age ≤40a years <0.001
40 – 49 years 0.61 0.38 0.98 0.041
50 – 59 years 0.65 0.41 1.02 0.062
60 – 69 years 0.45 0.28 0.70 <0.001
>70 years 0.34 0.21 0.57 0.000
Months after current 
diagnoses 0 – 6a 0.020
>6 – 12 1.24 0.92 1.65 0.154
>12 – 24 1.70 1.21 2.40 0.002
>24 1.20 0.88 1.64 0.259
a Reference category.
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ence in the 12-month prevalence between distinct cancer 
entities except for a higher risk in patients with head and 
neck cancer, which might be a result of the severe impair-
ments following surgery and further cancer treatments in 
this group  [37] . The high prevalence of nicotine abuse, e.g. 
in patients with head and neck cancer, can only partly ac-
count for this – particularly with regard to the lifetime 
prevalence. Excluding nicotine abuse from the set of men-
tal disorders, the highest prevalence rates (over 40%) were 
found in patients with the following cancer entities: ma-
lignant melanoma, breast cancer, female genital organs, 
kidney/urinary tract, and haematological malignancies, 
and the lowest prevalence (below 30%) rates in patients 
with lung cancer, bladder and prostate cancer. 
 In addition, other patterns of mental disorders could 
be observed: breast cancer patients and patients with ma-
lignant melanoma showed a high prevalence in anxiety 
and mood disorders and a low prevalence of nicotine de-
pendence. On the other hand, somatoform disorders 
were less pronounced in patients with head and neck can-
cer, as well as bladder cancer, but a higher prevalence in 
nicotine dependence was found. 
 In comparison with the general German population, 
the prevalence estimates in our total cancer population 
were higher. Lifetime prevalence of any mental disorder 
in the German population ranges from 43 to 45% in com-
parison with 56% in the total sample in our study  [24, 38, 
39] . The 12-month prevalence is also higher in cancer pa-
tients (39%) compared with the general population in 
Germany (28–31%)  [24, 38] . Considering different men-
tal diagnoses reveals that anxiety disorders, mood disor-
ders and somatoform disorders are more often found in 
cancer patients, while other mental disorders have preva-
lence rates closer to that in the general population, e.g. 
nicotine dependence  [24, 40] . 
 Our findings revealed no significant differences in the 
12-month prevalence estimates of mental disorders be-
tween different cancer care settings indicating the need 
for provision of continuous psycho-oncological support 
from inpatient to outpatient cancer care facilities. Our 
findings that men have a lower risk for developing a men-
tal disorder are in accordance with studies in the general 
population, although the causes of these gender differ-
ences in prevalence rates are not well understood so far. 
Possible theories include response bias, biological, social, 
and demographic influences as well as internalizing ver-
sus externalizing liability structure of psychopathology 
 [41] . Our analyses also showed a lower risk for mental 
disorders in elderly patients demonstrating the particular 
supportive care needs for younger patients.
 The results of our study are novel and important with 
regard to the planning of psycho-oncological interven-
tions and services tailored to the specific needs of differ-
ent cancer patient populations; however, they must be 
considered in the light of study limitations. Our sample is 
biased towards younger age and higher school education, 
which might result in an underestimation of the lifetime 
prevalence of mental disorders given that older patients 
and patients with lower school education are more likely 
to develop a mental disorder. Also, differences in patients’ 
response rate between study centres and a rate of 20.6% 
of patients who withdrew from completing the CIDI-O 
after having been assigned to it may limit the generaliz-
ability of our prevalence estimates. A further limitation of 
our study is that we have no information on concomitant 
medical illness, besides cancer, and specific treatments.
 Nevertheless, our study is one of the few more recent 
studies based on a broad representative cancer sample in-
terviewed in a standardized clinical interview to estimate 
the prevalence of mental disorders. The reported preva-
lence of mental disorders in cancer patients should sensi-
tize clinicians to a possible manifestation of mental disor-
ders across all stages of cancer inpatient and outpatient 
care. Our findings show that mental disorders are a com-
mon problem in cancer patients and emphasize the need 
for tailored psycho-oncological and psychotherapeutic 
support leading to an appropriate allocation of direct per-
sonnel and others resources. It might also be appropriate 
to consider the development of tumour-entity-specific 
(survivorship) care models.
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